Both in Biotechnology
Fate Therapeutics vs Inhibikase Therapeutics
Over the past year FATE returned +88.1% and IKT returned +26.9%; their daily moves had a correlation of 0.21.
FATE +88.1% IKT +26.9%Growth of $1, one year, split-adjusted
| Metric | FATE | IKT |
|---|---|---|
| Price | $2.37 | $2.06 |
| Market cap | $284.0M | $286.7M |
| Today | −0.42% | +1.73% |
| 1 month | −0.8% | −11.0% |
| 6 months | +97.5% | +22.3% |
| Year to date | +141.2% | +0.2% |
| 1 year | +137.0% | +34.3% |
| Revenue growth (YoY) | +9.2% | — |
| Gross margin | 100.0% | — |
| Net margin | −1448.6% | — |
| P/E (TTM) | — | — |
| Price / sales | 43.7× | — |
| Net cash | $153.8M | $159.0M |
| Dividend yield | — | — |
| Volatility (60d) | 59.5% | 49.3% |
| Short % of float | 9.2% | 17.8% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).